Porakishvili N, Kulikova N, Jewell A P, Youinou P Y, Yong K, Nathwani A, Heelan B, Duke V, Hamblin T J, Wallace P, Ely P, Clark E A, Lydyard P M
Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, London, UK.
Br J Haematol. 2005 Nov;131(3):313-9. doi: 10.1111/j.1365-2141.2005.05775.x.
We have studied the surface expression of the Toll-like receptor family member CD 180 on cells from 78 patients with B-chronic lymphocytic leukaemia (B-CLL). B-CLL cells had variable levels of CD 180 expression, but this was always less than that expressed by normal blood B cells and was stable for 24 months. Significantly higher levels of CD 180 were expressed by B-CLL cells with mutated IGVH genes compared with those using unmutated IGVH genes. This was in contrast to the higher levels of expression of surface immunoglobulin M by B-CLL cells using unmutated, rather than mutated IGVH genes. CD 180 was functional on B-CLL cells from some of the patients, as shown by the increased expression of CD 86 following incubation in vitro with anti-CD 180. The differential expression of CD 180 amongst B-CLL patients is one more marker that may define more precisely the different biological properties of this heterogeneous disease.
我们研究了78例B细胞慢性淋巴细胞白血病（B-CLL）患者细胞上Toll样受体家族成员CD 180的表面表达情况。B-CLL细胞的CD 180表达水平各异，但始终低于正常血液B细胞，且在24个月内保持稳定。与使用未突变IGVH基因的B-CLL细胞相比，具有突变IGVH基因的B-CLL细胞表达的CD 180水平显著更高。这与使用未突变而非突变IGVH基因的B-CLL细胞表面免疫球蛋白M表达水平更高形成对比。如体外与抗CD 180孵育后CD 86表达增加所示，CD 180在部分患者的B-CLL细胞上具有功能。B-CLL患者中CD 180的差异表达是又一个可能更精确界定这种异质性疾病不同生物学特性的标志物。
